A Phase 2 Trial of Cabozantinib for the Treatment of Radioiodine-Refractory Differentiated Thyroid Carcinoma in the First-Line Setting
Publication/Presentation Date
4-2018
Volume
100
Issue
5
First Page
1311
Last Page
1311
Published In/Presented At
Disciplines
Medicine and Health Sciences
Department(s)
Hematology-Medical Oncology Division
Document Type
Article
COinS